PLUS THERAPEUTICS, INC. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$5M
Cost of Revenue
—
Gross Profit
—
R&D
$8M
D&A
$445K
Operating Income
$-15M
EBITDA
$-15M
Interest Expense
$548K
Interest Income
$116K
Other Income/Expense
$-7M
Pretax Income
$-22M
Tax Provision
$0
Net Income
$-22M
Gross Margin
—
Operating Margin
-293.5%
Net Margin
-429.4%
Effective Tax Rate
0.0%
Deferred Tax Assets
$15K
Deferred Tax Liabilities
$0
DTA Valuation Allowance
$26M
Tax Credit Carryforwards
$2M
NOL Carryforwards
$19M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
-21.0%
ETR State + Local (pp)
-0.2%
ETR Foreign Differential (pp)
0.0%
Operating Lease Cost
$62K
Revenue YoY Variation
-10.5%
Income YoY Variation
-4.1%